Cantargia, BioWa extend ongoing collaboration around POTELLIGENT technology

This article was originally published here

Since the original agreement allowing use of POTELLIGENT® Technology was signed in 2015, Cantargia has advanced CAN04 to phase IIa clinical development for potential use in the treatment

The post Cantargia, BioWa extend ongoing collaboration around POTELLIGENT technology appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply